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OBJECTIVE: Muscle wasting contributes to the reduced quality of life and increased mortality in chronic
obstructive pulmonary disease (COPD). Muscle atrophy in mice with cachexia was caused by Activin A binding to
ActRIIB. The role of circulating Activin A leading to muscle atrophy in COPD remains elusive.
METHODS: In the present study, we evaluated the relationship between serum levels of Activin A and skeletal
muscle wasting in COPD patients. The expression levels of serum Activin A were measured in 78 stable COPD
patients and in 60 healthy controls via ELISA, which was also used to determine the expression of circulating
TNF-a levels. Total skeletal muscle mass (SMM) was calculated according to a validated formula by age and
anthropometric measurements. The fat-free mass index (FFMI) was determined as the fat-free mass (FFM)
corrected for body surface area.
RESULTS: Compared to the healthy controls, COPD patients had upregulated Activin A expression. The elevated
levels of Activin A were correlated with TNF-a expression, while total SMM and FFMI were significantly decreased
in COPD patients. Furthermore, serum Activin A expression in COPD patients was negatively associated with both
FFMI and BMI.
CONCLUSION: The above results showed an association between increased circulating Activin A in COPD patients
and the presence of muscle atrophy. Given our previous knowledge, we speculate that Activin A contributes to
skeletal muscle wasting in COPD.
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’ INTRODUCTION
As a degenerative systemic manifestation, skeletal muscle
atrophy contributes to a determinant of mortality indepen-
dent of airway obstruction in chronic obstructive pulmonary
disease (COPD) (1,2). Traditionally, skeletal muscle atrophy
as selective depletion of fat-free mass index (FFMI) and body
mass index (BMI) disturbs the potential balance of muscle
protein synthesis and degradation in 20-40% of COPD
patients depending on definition and disease stage, resulting
in decreased muscle function and adaptive capacity (3,4).
Total skeletal muscle mass (SMM) constitutes more than half
of the total body mass. As an important indicator of nutrition
and metabolic function, declining SMM is recognized as
having adverse effects on health (5,6). It is necessary to
investigate the biological factors inducing muscle atrophy
in COPD.
The mechanisms of muscle mass atrophy are highly
complex. Li et al. found that TNF-a acted to induce skeletal
muscle atrophy in vivo and in vitro (7). Recent research has
reported the activated role of Activin A (Act A) on muscle
mass degradation via binding to Activin receptor-IIB (ActRIIB)
in cachectic mice with lung cancer (8). Act A, a superfamily
of transforming growth factor-b (TGF-b), was found to be
an inducer of muscle degradation in cachectic mice (9).
Although Act A is closely associated with inflammation (10),
it is unclear whether serum Act A contributes to muscle
wasting in COPD.
Based on previous studies, we hypothesized that serum
Act A resulted in muscle wasting in COPD with low BMI,
FFMI and SMM. In this study, we measured circulating levels
of Act A and correlation with serum TNF-a levels, BMI,
FFMI and SMM to investigate the association between Act A
and muscle atrophy in COPD.
’ MATERIALS AND METHODS
Patients and study design
This study was performed at Yixing Hospital, Affiliated
Jiangsu University, and approved by the ethical committee ofDOI: 10.6061/clinics/2019/e981
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Jiangsu University. All participants in this study provided
written informed consent. The study methodologies con-
formed to the standards set by the Declaration of Helsinki. A
total of 78 patients with stable COPD and 60 aged-matched
healthy controls who smoked for more than 10 years were
enrolled. COPD was diagnosed based on criteria (11) showing
irreversible airflow obstruction via spirometry (forced expira-
tory volume in 1s (FEV1) o80% predicted value and FEV1/
forced vital capacity (FVC)o70%). All COPD patients were in
stable condition at the time of study without any exacerbation
of disease or systemic corticosteroid administration within
2 months of their participation in this test. Patients with any
comorbid condition associated with muscle wasting (i.e.,
active inflammatory, illnesses, cancer, congestive heart failure,
chronic renal failure or denervation) were excluded.
Pulmonary function and inflammatory testing
According to well-established methods (12), effective
pulmonary function tests, includingQ4 spirometry, lung volume
with body plethysmography, and diffusion carbon monoxide
diffusion capacity were used in all patients and controls
during the initial evaluation.
As described previously (13), in order to exclude airway
inflammation as a disturbing factor, all participants were
examined for the fraction of exhaled nitric oxide (FeNO).
Anthropometric measurements and body
composition
As in a previous report (14), SMM was determined by a
validated formula using age and anthropometric measure-
ments. The main parameters of this formula were body
height and skinfold corrected limb circumferences as skin-
fold corrected upper-arm girth (CAG), skinfold corrected calf
girth (CCG) and skinfold corrected thigh girth (CTG). Accord-
ing to the standardized anatomic locations (14) and the spe-
cific methods (15), circumference measurements were carried
out on all participants.
We used dual energy X-ray absorptiometry (DEXA) to
provide regional measurements of the FFMI and FFM
(General Electric Healthcare, Chicago, IL). FFM was mea-
sured from the sum of lean mass and bone mineral content.
Moreover, the FFMI was derived from FFM normalized to
body surface area. Muscle atrophy was defined as an FFMI
less than 15 kg/m2 in women and 17 kg/m2 in men, as
reported previously (16,17).
Serum biomarker measurements
Peripheral venous blood was collected from each partici-
pant between 7 am and 8 am after fasting since 9 pm the
previous night as standardized conditions. Serum Activin A
and TNF-a were measured using enzyme-linked immunoas-
says (ELISA) kits (R&D Systems, USA) according to the
manufacturer’s recommendations.
Statistical analysis
Data for comparison of unpaired parameters between
patients and controls were analyzed with Student’s t test via
SigmaStat software as indicated. The relationship between
Act A and other parameters was confirmed via linear
regression correlation analysis. A p-value o0.05 was con-




Anthropometric characteristics, pulmonary function data
and FeNO results are presented in Table 1. Patients with
COPD exhibited significant airflow obstruction in line with
reduced FEV1 levels and FEV1/FVC ratios as diagnostic
criteria of COPD. BMI index attenuation was established in
patients with COPD, while there was no significant
difference in terms of age and sex compared with controls.
In addition, there were 58 cases among all COPD patients
with malnutrition according to a BMI of less than 21 kg/m2
as previously reported (15,18) and low FFMI. To eliminate
the effects of airway inflammation on Act A expression, we
used a FeNO value greater than 25 ppb as a criterion to
exclude patients. There was no significant difference in the
FeNO results between the two groups.
Muscle characteristics
As described in Table 2, total body SMM with regards to
reliable value and its ratio to body weight was reduced in
Table 1 - General characteristics of the enrolled participants.
COPD (N=78) Control (N=60) p-value
Sex, M (%) 52 (66.7) 35 (58.3) 0.31
Age, (yrs) 67.12±8.37 61.92±6.58 0.26
BMI (kg/m2) 19.25±3.25 23.31±4.41 o0.01
FeNO (ppb) 22.16±5.73 20.26±7.72 0.2
FEV1 pred (%) 53.66±5.23 89.18±6.18 o0.01
FEV1/FVC (%) 47.73±8.22 88.78±4.39 o0.01
RV/TLC (%) 33.45±4.86 29.11±3.65 0.38
DLco (ml/m/mmHg) 24.78±7.42 28.35±8.46 0.35
PH 7.41±0.14 7.38±0.22 0.36
PaO2 (mmHg) 78.29±10.76 82.71±13.41 0.27
PaCO2 (mmHg) 33.71±9.15 39.26±10.47 0.25
Blood white cell count (109/L) 8.43±0.23 8.83±0.47 0.44
Blood neutrophil (109/L) 5.77±0.39 4.52±0.32 0.38
Blood eosinophil (109/L) 0.46±0.08 0.42±0.11 0.42
CRP (mg/L) 3.23±1.28 4.26±1.14 0.32
BMI, body mass index; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume at 1s; FVC, force vital capacity; PO2 oxygen partial pressure;
PCO2 carbon dioxide partial pressure; RV, residual volume; TLC, total lung capacity; DLco, total lung carbon monoxide transfer factor; CRP, C reactive
protein.
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patients with COPD (18.26±2.24 vs. 25.33±3.13). Conse-
quently, local SMM, such as CAG, CTG and CCG, was
also significantly decreased in COPD patients compared
with controls. Additionally, COPD patients showed remark-
able loss of muscle mass, such as reductive FFM and
FFMI, as well as other anthropometric measurements
(16.27±2.06 vs. 22.64±2.73).
Serum expression of Action A and TNF-a levels
Interestingly, the mean levels of systemic Act A were
absolutely elevated in patients with COPD (13.12±3.87 vs.
7.28±2.06), whereas serum levels of TNF-a as an important
inflammatory factor playing a central role in the patho-
physiology in muscle atrophy were also upregulated in
COPD patients when compared with controls (9.36±3.18 vs.
6.03±1.86) (Figure 1).
Correlations between serum Act A levels and
other parameters
As shown in Figure 2, regression correlation analysis
indicated a significant positive correlation between systemic
Act A levels and TNF-a concentrations in patients with
COPD (R2=0.041, p=0.025). In addition, serum Act A expres-
sion was inversely correlated with BMI in COPD patients
(R2=0.021, p=0.004). A negative correlation was also observed
between serum Act A and SMM in COPD patients (R2=0.017,
p=0.01). In addition, regression correlation analysis showed
the inverse correlation between circulation Act A levels and
FFMI as an indicator of muscle function (R2=0.013, p=0.008).
’ DISCUSSION
The current study reveals that elevated circulating levels
of Act A in COPD are associated with muscle atrophy as
shown by reductions in BMI, SMM and FFMI. To the best of
our knowledge, this is the first report on the relationship
between serum Act A and muscle wasting in COPD. Never-
theless, it is necessary to highlight the importance of abnor-
mal serum Act A levels in relation to the muscle mass
regulation of COPD patients.
Several previous studies explored that muscle atrophy as a
systemic complication of whole body weight is commonly
detected in 10%-40% of COPD patients (19). In our study, we
also found muscle atrophy in COPD patients showing
decreased total-body SMM with regards to its absolute value
and its percentage of body weight, as well as BMI. Indeed,
the reduced SMM and BMI levels in our data were in line
with recent reports of muscle wasting and malnutrition in
COPD patients (15,20,21). A previous study reported that the
continued loss of protein in muscle mass leads to muscle
fiber shrinkage and a reduction in the muscle cross-sectional
area (CSA), resulting in marked muscle wasting (22). Some
researchers have explored the reduction in FFM and FFMI as
malnutrition and muscle atrophy (17) were significant in
COPD patients. Interestingly, consistent with these data, we
also noticed that there were obvious decreases in FFM and
the FFMI in COPD. Although the ECLIPSE group reported
elevated BMI and FFMI in a subgroup of COPD patients
with persistent systemic inflammation (23), Barker et al.
showed that FFM and FFMI levels, such as nutritional
depletion and progressive muscle atrophy, were not related
to airway inflammation or bacterial colonization (17,24).
Furthermore, to remove the impact of systemic and airway
inflammation on muscle atrophy, we excluded not only
patients with persistent oral glucocorticoid use in our
research study but also patients with serum CRP and FeNO
levels in COPD and controls. Our data showed a marked
reduction in BMI, SMM and FFMI as muscle atrophy in
COPD patients but not in healthy controls.
In addition to abnormal conditions, such as denervation,
fasting, disuse, oxidative stress and hypoxia (25-27), a number
of factors, such as myostatin and Act A, are responsible for
muscle weakness due to protein degradation and intrinsic
metabolic abnormalities (28,29). Indeed, as a major subfamily
Figure 1 - Serum levels of Activin A and TNF-a in COPD patients. A: Elevated serum Activin A levels were present in COPD patients
relative to controls. B: Serum TNF-a levels were significantly increased in patients with COPD.
Table 2 - Muscle characteristics in COPD patients and controls.
COPD (N=78) Control (N=60) p-value
CAG (cm) 17.31±2.15 23.65±2.78 o0.01
CTG (cm) 31.63±4.11 44.82±3.09 o0.01
CCG (cm) 24.07±2.17 29.38±2.84 o0.01
SMM (kg) 18.26±2.24 25.33±3.13 o0.01
SMM/Wt (%) 28.85±3.99 40.27±3.77 o0.01
FFM (kg) 41.28±3.91 53.27±2.28 o0.01
FFMI (kg/m2) 16.27±2.06 22.64±2.73 o0.01
CAG, skinfold corrected upper-arm girth; CTC skinfold corrected thigh
girth; CCG, skinfold corrected calf girth; SMM, total body skeletal mass;
Wt, weight; FFM, fat-free mass; FFMI, fat-free mass index.
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of TGF-b (30), Act A has a wide range of biological effects on
wound healing, cell proliferation and differentiation, immune
response and angiogenesis (31,32). Upregulated Act A has
been shown in many catabolic disease states, including
ovarian cancer, endometrial adenocarcinoma, prostate, multi-
ple myeloma, esophageal, breast and pancreatic cancers, and
noncancer settings, such as chronic renal failure, heart failure,
and pulmonary hypertension (33). Most intriguingly, Act A
maintenance at high levels in the serum and tumor tissue of
cachectic cancer patients suggested its involvement in the
pathogenesis of muscle wasting (10,33). Beyond its classic
roles, Act Awas established as a paracrine/autocrine factor in
non-gonadal tissues, including skeletal and heart muscles.
Mice treated with Act A experienced an approximately 30%
decrease in muscle mass (8). In addition, inhibition of Act A
expression by its antagonist follistatin prevented skeletal
muscle from insistent degradation. Moreover, recent evidence
suggested that Activin A activated signaling in the develop-
ment and progression of muscle wasting via the ActRIIB,
which may be regarded as a therapeutic target for cachexia (8).
In line with the observation showing the upregulated exp-
ression of Act A in the airway epithelium, airway smooth
muscle and alveolar macrophages of COPD patients (10,34),
we found increased circulating levels of Act A in COPD
patients. Furthermore, to the best of our knowledge, we
established the first negative correlations between elevated
serum levels of Act A and muscle mass index as BMI, SMM
and FFMI in our study, which indicated the contributing role
of Act A in muscle degradation in COPD. Together with
previous evidence of increased Act A levels with muscle
atrophy, our findings indicated a closing linkage of serum Act
A levels with skeletal muscle wasting and cachexia in COPD.
Some previous reports indicated the relationship of muscle
atrophy with elevated TNF-a (previously named cachectin)
due to its tissue depletion and body weight loss abilities (35).
Consistent with the results showing elevated TNF-a mRNA
levels, which play a key role in the pathophysiology of
COPD (36), our study also described increased serum TNF-a
levels in patients compared with controls. Indeed, TNF-a
was involved in the development of skeletal muscle degra-
dation resulting in loss of muscle mass and function (37).
Further studies found that elevated TNF-a in COPD was
inversely correlated with SMM and BMI (15). In our study,
we further investigated the relationship between Act A and
TNF-a to understand the mechanisms of muscle atrophy
more clearly. We found a positive correlation between
circulating Act A and TNF-a in COPD. Together with the
literature, we suggest that increasing serum Act A levels
might be stimulated by TNF-a, leading to more significant
skeletal muscle wasting in COPD.
Figure 2 - Correlation between Act A levels and indicators of muscle wasting in COPD. A: Positive correlation between Act A and TNF-a
levels in COPD patients. B: Negative correlation between Act A and BMI in COPD patients (B) and SMM (C) and FFMI (D).
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Our data first demonstrated that circulating Act A was
markedly increased in COPD patients. Muscle wasting in
COPD was positively related to elevated Act A and TNF-a
but negatively correlated with BMI, FFMI and SMM. We
speculated that elevated serum Act A might contribute to
muscle atrophy and weight loss in COPD patients.
Our major limitation in this study was the small
population of COPD patients, especially when stratified by
gender. Future studies will focus on the mechanisms of Act
A-induced muscle wasting in COPD. Nevertheless, although
limited, our data are sufficient to support the importance of
Act A in COPD patients.
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